Results 201 to 210 of about 190,806 (273)

Isocitrate dehydrogenase of soybeans.

Indian journal of biochemistry & biophysics, 1975
R C, Gupta, R, Narayan
openaire   +1 more source

Glucose Hypometabolic Pattern and Prediction of Isocitrate Dehydrogenase Status in Non-Contrast-Enhanced Glioma Using Z-Score-Based ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography. [PDF]

Cancers (Basel)
Imai N, Yano H, Ikegame Y, Yasuda S, Morishima R, Kumagai Y, Ikuta S, Maruyama T, Ohe N, Kumagai M, Muragaki Y, Shinoda J, Izumo T.   +12 more
europepmc   +1 more source

Poor diagnostic value of isocitrate dehydrogenase 1 R132H immunohistochemistry for determination of isocitrate dehydrogenase 1 status in patients with glioblastoma. [PDF]

Surg Neurol Int
Faried A, Hadi EJ, Agustina H.
europepmc   +1 more source

3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma. [PDF]

J Neuropathol Exp Neurol
Voong V, Beccari S, Hashemi E, Kriener B, Mathur R, Lafontaine M, Shai A, Lupo JM, Chang EF, Hervey-Jumper SL, Berger MS, Waszak SM, Costello JF, Phillips JJ.   +13 more
europepmc   +1 more source

The PRIME trial: An investigator‐initiated, multicentre, phase II study of the poly(ADP‐ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)‐mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes

British Journal of Haematology, Volume 209, Issue 4, Page 1891-1895, October 2026.
Rory M. Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R. Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F. Little, Steven D. Gore, Jing Li, Xun Bao, Li Chen, Sayak Ghatak, Thomas Prebet, Ranjit S. Bindra, Amer M. Zeidan, Stephanie Halene   +18 more
wiley   +1 more source

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia. [PDF]

Br J Haematol
Moore CG, Chyong DI, Daver N, Aubrey BJ, Marx KR, Takahashi K, Abaza Y, Smith CC, Amrein PC, Hock H, Hobbs G, Narayan R, Lee MH, Moran JA, Bergeron M, Foster JE, Perl AE, Levis MJ, DiNardo CD, Brunner AM, Fathi AT.   +20 more
europepmc   +1 more source

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology. [PDF]

Asia Pac J Clin Oncol
Pinkham MB, Sim HW, Jeffree RL, Lasocki A, Legge DM, Saran F, Satgunaseelan L, Gan HK.   +7 more
europepmc   +1 more source

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia. [PDF]

Adv Ther
Watts JM, Wang ES, Jonas BA, Wilson FR, Park JE, Cope S, Sheppard A, Thomassen A, de Botton S, Cortes JE.   +9 more
europepmc   +1 more source

Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas. [PDF]

Neuro Oncol
Arakawa Y, Saito R, Kanemura Y, Mishima K, Koriyama S, Narita Y, Kumabe T, Motomura K, Sugiyama K, Yamasaki F, Mukasa A, Kanamori M, Kuga D, Nagane M, Kakurai Y, Isobe K, Nakamura H.   +16 more
europepmc   +1 more source